Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/6245

Target Organs and Levels of Evidence for TR-467

Toxicology and Carcinogenesis Studies of Chloroprene (CASRN 126-99-8) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Chloroprene
126-99-8		 12/11/1996 Inhalation
R&M: 0, 12.8, 32.0, OR 80.0 PPM; 50/SEX/SPECIES/GROUP		 Battelle Northwest Laboratory

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50
  • Thyroid Gland Follicular Cell: ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50
  • Lung: Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50
  • Kidney Tubular Cell: (SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50
May Have Been Related
  • Urinary Bladder: TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49
Non-Neoplastic Lesions
  • LUNG: ALVEOLAR EPITHELIUM HYPERPLASIA
  • KIDNEY: INCREASED SEVERITY OF NEPHROPATHY
  • NASAL CAVITY: (OLFACTORY EPITHELIUM) ATROPHY; FIBROSIS; HYPERPLASIA; CHRONIC INFLAMMATION; METAPLASIA; NECROSIS
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50
  • Thyroid Gland Follicular Cell: ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50
  • Mammary Gland: FIBROADENOMA 24/49 32/50 36/50 36/50
  • Kidney Tubular Cell: (SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50
May Have Been Related
  • Lung: Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50
  • Urinary Bladder: TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50
Non-Neoplastic Lesions
  • LUNG: ALVEOLAR EPITHELIUM HYPERPLASIA
  • KIDNEY: INCREASED SEVERITY OF NEPHROPATHY
  • NASAL CAVITY: (OLFACTORY EPITHELIUM) ATROPHY; FIBROSIS; HYPERPLASIA; CHRONIC INFLAMMATION; METAPLASIA, NECROSIS
Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Lung: Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50
  • Vascular System (Unspecified): HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50
  • Harderian Gland: ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50
  • Kidney Tubular Cell: (SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50
Non-Neoplastic Lesions
  • LUNG: BRONCHIOLE HYPERPLASIA; HISTIOCYTIC CELL INFILTRATION
  • FORESTOMACH: EPITHELIAL HYPERPLASIA
  • KIDNEY: RENAL TUBULE HYPERPLASIA
  • NASAL CAVITY: (OLFACTORY EPITHELIUM) ATROPHY; METAPLASIA; HYPERPLASIA
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION
Female Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Lung: Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50
  • Vascular System (Unspecified): HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50
  • Harderian Gland: ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50
  • Mammary Gland: CARCINOMA 3/50 4/50 7/50 12/50
  • Liver: ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50
  • Subcutaneous Tissue: SARCOMA 0/50 11/50 11/50 18/50
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): SARCOMA 0/50 4/50 8/50 3/50
  • Zymbal Gland: CARCINOMA 0/50 0/50 0/50 3/50
  • Forestomach: Squamous Cell Papilloma 0/50 0/50 0/50 4/50
Non-Neoplastic Lesions
  • LUNG: BRONCHIOLE HYPERPLASIA; HISTIOCYTIC CELL INFILTRATION
  • FORESTOMACH: EPITHELIAL HYPERPLASIA
  • NASAL CAVITY: (OLFACTORY EPITHELIUM) ATROPHY; METAPLASIA; HYPERPLASIA
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION


Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Chloroprene
126-99-8		 Inhalation
R:0,32,80,200,500PPM M:0,12,32,80,200PPM		 Battelle Northwest Laboratory

Levels of Evidence: None